Enanta Pharmaceuticals Inc (ENTA)

[willyw]

Paxlovid does not work in standard risk patients. Check your data. EDP-235 won’t work either.

Ask yourself; what is the bar to approval?
According to you it seems to be incredibly low if Paxlovid doesn't work.

https://www.globaldata.com/media/pharma/top-selling-covid-19-drug-paxlovid-see-sales-decrease-2023-following-second-booster-says-globaldata/

"Although many pharmaceutical companies have launched therapeutic drugs for COVID-19, Pfizer’s Paxlovid takes the top spot as market leader. The drug has expected peak sales of $30.7 billion in 2022 and total generated sales of $81 billion between 2021 and 2028, according to GlobalData, a leading data and analytics company."

So..... if Enanta's compound were better, more efficacious, once a day without boosting it would seem approval would be simple since the bar is so incredibly low.